Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Epigenetic mechanisms underlying maternal diabetes-associated risk of congenital heart disease
Madhumita Basu, … , Zhe Han, Vidu Garg
Madhumita Basu, … , Zhe Han, Vidu Garg
Published October 19, 2017
Citation Information: JCI Insight. 2017;2(20):e95085. https://doi.org/10.1172/jci.insight.95085.
View: Text | PDF
Research Article Cardiology Genetics

Epigenetic mechanisms underlying maternal diabetes-associated risk of congenital heart disease

  • Text
  • PDF
Abstract

Birth defects are the leading cause of infant mortality, and they are caused by a combination of genetic and environmental factors. Environmental risk factors may contribute to birth defects in genetically susceptible infants by altering critical molecular pathways during embryogenesis, but experimental evidence for gene-environment interactions is limited. Fetal hyperglycemia associated with maternal diabetes results in a 5-fold increased risk of congenital heart disease (CHD), but the molecular basis for this correlation is unknown. Here, we show that the effects of maternal hyperglycemia on cardiac development are sensitized by haploinsufficiency of Notch1, a key transcriptional regulator known to cause CHD. Using ATAC-seq, we found that hyperglycemia decreased chromatin accessibility at the endothelial NO synthase (Nos3) locus, resulting in reduced NO synthesis. Transcription of Jarid2, a regulator of histone methyltransferase complexes, was increased in response to reduced NO, and this upregulation directly resulted in inhibition of Notch1 expression to levels below a threshold necessary for normal heart development. We extended these findings using a Drosophila maternal diabetic model that revealed the evolutionary conservation of this interaction and the Jarid2-mediated mechanism. These findings identify a gene-environment interaction between maternal hyperglycemia and Notch signaling and support a model in which environmental factors cause birth defects in genetically susceptible infants.

Authors

Madhumita Basu, Jun-Yi Zhu, Stephanie LaHaye, Uddalak Majumdar, Kai Jiao, Zhe Han, Vidu Garg

×

Figure 5

NO mediated Jarid2 repression restores Notch1 expression.

Options: View larger image (or click on image) Download as PowerPoint
NO mediated Jarid2 repression restores Notch1 expression.
(A) Immunoblot...
(A) Immunoblot showing JARID2 and N1ICD levels in normoglycemic AVM cells treated with 250 μM DetaNONOate and 250 μM cPTIO as NO donor and quencher for 48 hours. The graph shows quantification (n = 3; mean ± SEM; *P < 0.05, 2-tailed Student’s t test). (B) Jarid2 and Notch1 mRNA expression and (C) JARID2 and N1ICD protein levels in AVM cells cultured in NG (5.5 mM) and HG (25 mM) with 250 μM DetaNONOate. 0.01 M NaOH served as vehicle control. Immunoblot quantification in C (n ≥ 3; mean ± SEM; #P < 0.05 by 2-tailed Student’s t test, not significant with Holm-Bonferroni correction). (D and E) RT-qPCR and representative immunoblot showing expression of Jarid2 and N1ICD in AVM cells after treatment with Jarid2 siRNA or control siRNA cultured in NG or HG. Immunoblot quantification in E (n ≥ 3; mean ± SEM; *P < 0.05, 2-tailed Student’s t test with Holm-Bonferroni correction in B, D, and E).

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts